Verrica Pharmaceuticals Inc. (VRCA)
USD 0.58
(-10.23%)
USD 0.58
(-10.23%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -38.57 Million | -18.65 Million | -27.58 Million | -30.2 Million | -27.4 Million | -17.87 Million |
| Net Income | -66.99 Million | -24.48 Million | -35.08 Million | -42.69 Million | -28.2 Million | -20.64 Million |
| Depreciation & Amortization | 836 Thousand | 718 Thousand | 472 Thousand | 229 Thousand | 257 Thousand | 20 Thousand |
| Deferred income taxes | 1.65 Million | - | 66 Thousand | -138 Thousand | - | - |
| Stock-based compensation | 14.37 Million | 4.98 Million | 6.05 Million | 9.82 Million | 3.33 Million | 2.25 Million |
| Change in working capital | 9.85 Million | -1.8 Million | -535 Thousand | 1.63 Million | -1.72 Million | 938 Thousand |
| Other non-cash items | 1.68 Million | 1.93 Million | 1.44 Million | 940 Thousand | -1.06 Million | -435 Thousand |
| Investing Cash Flow | -362 Thousand | 54.04 Million | -998 Thousand | -3.58 Million | 25.95 Million | -79.89 Million |
| Investments in PPE | -362 Thousand | -302 Thousand | -883 Thousand | -1.47 Million | -682 Thousand | -774 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -4.48 Million | -68.91 Million | -71.73 Million | -89.85 Million | -79.12 Million |
| Sales/Maturities of investments | - | 59 Million | 69 Million | 69.84 Million | 117.71 Million | - |
| Other Investing Activities | - | -180 Thousand | -201 Thousand | -221 Thousand | -1.22 Million | -499 Thousand |
| Financing Cash Flow | 74.21 Million | -16.87 Million | 33.64 Million | 35.23 Million | 423 Thousand | 99.37 Million |
| Debt repayment | -44.1 Million | -43.75 Million | -5000.00 | -34.16 Million | -119 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 30.13 Million | 26.9 Million | 28.11 Million | 453 Thousand | 423 Thousand | 86.25 Million |
| Other Financing Activities | 88.18 Million | -17 Thousand | 5.53 Million | 68.94 Million | 119 Thousand | 13.12 Million |
| Accounts receivables | -3.92 Million | -487 Thousand | - | - | - | - |
| Accounts payables | 2.2 Million | -338 Thousand | 497 Thousand | -838 Thousand | 225 Thousand | 793 Thousand |
| Inventory | - | 487 Thousand | - | - | - | - |
| Other working capital | 11.58 Million | -1.46 Million | -1.03 Million | 2.47 Million | -1.95 Million | 145 Thousand |
| Cash at beginning of period | 34.27 Million | 15.75 Million | 10.68 Million | 9.24 Million | 10.27 Million | 8.66 Million |
| Cash at end of period | 69.54 Million | 34.27 Million | 15.75 Million | 10.68 Million | 9.24 Million | 10.27 Million |
| Capital Expenditure | -362 Thousand | -302 Thousand | -883 Thousand | -1.47 Million | -682 Thousand | -774 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 35.27 Million | 18.52 Million | 5.06 Million | 1.44 Million | -1.03 Million | 1.6 Million |
| Free Cash Flow | -38.93 Million | -18.95 Million | -28.46 Million | -31.67 Million | -28.09 Million | -18.64 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -22.86 Million | -17.18 Million | -20.33 Million | -66.99 Million | -24.61 Million | -24.8 Million |
| Depreciation & Amortization | -140 Thousand | 334 Thousand | 340 Thousand | 836 Thousand | 217 Thousand | 353 Thousand |
| Deferred income taxes | - | - | - | 1.65 Million | -2.14 Million | 1.48 Million |
| Stock-based compensation | 2.1 Million | 2.22 Million | 2.07 Million | 14.37 Million | 2.07 Million | 9.66 Million |
| Change in working capital | 4.9 Million | -2.39 Million | -2.51 Million | 9.85 Million | 4.64 Million | -281 Thousand |
| Other non-cash items | 7.43 Million | 7.55 Million | 6.36 Million | 1.68 Million | 5.09 Million | -1.22 Million |
| Investing Cash Flow | -16 Thousand | -11 Thousand | - | -362 Thousand | -227 Thousand | -65 Thousand |
| Investments in PPE | -16 Thousand | -11 Thousand | - | -362 Thousand | -227 Thousand | -65 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -397 Thousand | -640 Thousand | -661 Thousand | 74.21 Million | 197 Thousand | 44.04 Million |
| Debt repayment | -905 Thousand | -790 Thousand | -665 Thousand | -44.1 Million | -224 Thousand | -44.02 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -1000.00 | - |
| Common Stock Issuance | -154 Thousand | 150 Thousand | 4000.00 | 30.13 Million | -5000.00 | -61 Thousand |
| Other Financing Activities | 662 Thousand | -463 Thousand | -505 Thousand | 88.18 Million | 426 Thousand | 88.13 Million |
| Accounts receivables | 10.19 Million | -2.61 Million | -3.17 Million | -3.92 Million | -344 Thousand | -3.89 Million |
| Accounts payables | -169 Thousand | -1.38 Million | 52 Thousand | 2.2 Million | 578 Thousand | 121 Thousand |
| Inventory | - | - | - | - | -3.58 Million | 3.89 Million |
| Other working capital | -2.21 Million | 1.6 Million | 614 Thousand | 11.58 Million | 7.99 Million | -402 Thousand |
| Cash at beginning of period | 31.93 Million | 48.93 Million | 69.54 Million | 34.27 Million | 84.3 Million | 55.14 Million |
| Cash at end of period | 22.95 Million | 31.93 Million | 48.93 Million | 69.54 Million | 69.54 Million | 84.3 Million |
| Capital Expenditure | -16 Thousand | -11 Thousand | - | -362 Thousand | -227 Thousand | -65 Thousand |
| Effect of forex changes on cash | - | - | - | - | 22.53 Million | -27.94 Million |
| Net cash flow / Change in cash | -8.97 Million | -17 Million | -20.6 Million | 35.27 Million | -14.76 Million | 29.16 Million |
| Free Cash Flow | -8.57 Million | -16.36 Million | -19.94 Million | -38.93 Million | -14.95 Million | -14.87 Million |
0146
ORA
SUL
OTTR
002381
GINISILK